Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SPRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpruce terminates Japan partnership for tildacerfont, forfeiting up to $65M in milestones
Filed March 20, 2026 · Period ending March 16, 2026 · ~1 min read
Key Changes
-
high
Spruce and Kaken mutually terminated their Japan collaboration for tildacerfont effective March 31, 2026, following a comprehensive assessment of the CAH treatment program. All development and commercialization rights revert to Spruce.
Item 1.02 verify on EDGAR → -
high
The company will forfeit up to $65 million in unearned development, regulatory, and commercialization milestone payments, plus future royalties from Japan sales. Spruce retains the $15 million upfront payment received in 2023.
Item 1.02 verify on EDGAR → -
high
The termination followed a comprehensive assessment of tildacerfont for CAH treatment, though specific findings were not disclosed. This raises questions about the drug's development prospects or commercial viability.
Item 1.02 verify on EDGAR → -
medium
No early termination penalties will be paid by Spruce, limiting immediate cash impact to the loss of future milestone and royalty opportunities rather than requiring cash outlays.
Item 1.02 verify on EDGAR →
Summary
Spruce Biosciences terminated its Japan partnership with Kaken Pharmaceutical for tildacerfont, its CAH treatment candidate, effective March 31, 2026. The mutual termination followed what the company describes as a "comprehensive assessment" of the program, though no details were provided about what that review revealed.
The move costs Spruce up to $65 million in potential milestone payments and future royalties, though the company keeps the $15 million upfront payment from 2023 and avoids termination penalties. For retail investors, this signals potential trouble with tildacerfont's development path or commercial prospects, at least in Japan.
When a partner walks away from exclusive rights after conducting a thorough review, it typically indicates concerns about clinical data, regulatory hurdles, or market opportunity. The lack of specifics is concerning—investors should watch for any updates on tildacerfont's global development status and whether similar assessments might affect other markets. The immediate financial impact is the loss of future revenue potential rather than cash outlays, but this materially reduces Spruce's long-term value proposition. Watch for the company's next earnings call or investor presentation for management's explanation of what the assessment found and how this affects their overall CAH strategy.
Section-by-Section Diff
Event · Item 1.02 — Termination of a Material Definitive Agreement
Item 1.02 — Termination of a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 16, 2026, Spruce Biosciences, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kaken Pharmaceutical Co., Ltd. (“Kaken”) to terminate by mutual agreement that certain Collaboration and License Agreement, dated as of January 5, 2023, by and between the Company and Kaken (the “Collaboration Agreement”). The Collaboration Agreement will terminate effective as of March 31, 2026 (the “Termination Date”) pursuant to the Termination Agreement, and from and after the Termination Date, the Collaboration Agreement is of no further force or effect except as otherwise expressly set forth in such agreement.
Spruce and Kaken mutually agreed to terminate their collaboration agreement for tildacerfont in Japan, effective March 31, 2026. The agreement, originally signed in January 2023, granted Kaken exclusive rights to develop, manufacture, and commercialize tildacerfont for congenital adrenal hyperplasia in Japan. The termination follows a comprehensive assessment of the tildacerfont program for CAH treatment.
Added in current filing · verify on EDGAR →
Under the terms of the Collaboration Agreement, the Company granted Kaken the exclusive right to develop, manufacture and commercialize tildacerfont for the treatment of congenital adrenal hyperplasia (“CAH”) in Japan. Pursuant to the Collaboration Agreement, Kaken made a non-refundable upfront payment to the Company of $15.0 million in April 2023.
The terminated agreement had granted Kaken exclusive rights to tildacerfont for CAH in Japan. Spruce received $15 million upfront in 2023, which remains with the company as it was non-refundable. The termination returns all development and commercialization rights for the Japan market back to Spruce.
Added in current filing · verify on EDGAR →
The parties mutually agreed to terminate the Collaboration Agreement following a comprehensive assessment of the tildacerfont program for the treatment of CAH.
The termination followed a comprehensive assessment of the tildacerfont CAH program, suggesting potential concerns about the drug's development prospects, commercial viability, or strategic fit in the Japan market. The filing does not provide specific details about what the assessment revealed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify